CN110201003A - 微生物区系的组合物及与其相关的方法 - Google Patents

微生物区系的组合物及与其相关的方法 Download PDF

Info

Publication number
CN110201003A
CN110201003A CN201910088168.5A CN201910088168A CN110201003A CN 110201003 A CN110201003 A CN 110201003A CN 201910088168 A CN201910088168 A CN 201910088168A CN 110201003 A CN110201003 A CN 110201003A
Authority
CN
China
Prior art keywords
subject
microorganism
bacteroidetes
microflora
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201910088168.5A
Other languages
English (en)
Chinese (zh)
Inventor
L·M·卡普兰
A·P·利奥
P·J·特恩博
J·L·哈里斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
Harvard University
Kenvue Brands LLC
Original Assignee
General Hospital Corp
Ethicon Endo Surgery Inc
Harvard University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49003107&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN110201003(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by General Hospital Corp, Ethicon Endo Surgery Inc, Harvard University filed Critical General Hospital Corp
Publication of CN110201003A publication Critical patent/CN110201003A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
CN201910088168.5A 2012-02-29 2013-02-28 微生物区系的组合物及与其相关的方法 Pending CN110201003A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261604824P 2012-02-29 2012-02-29
US61/604,824 2012-02-29
CN201380022545.6A CN104780932A (zh) 2012-02-29 2013-02-28 微生物区系的组合物及与其相关的方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201380022545.6A Division CN104780932A (zh) 2012-02-29 2013-02-28 微生物区系的组合物及与其相关的方法

Publications (1)

Publication Number Publication Date
CN110201003A true CN110201003A (zh) 2019-09-06

Family

ID=49003107

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201910088168.5A Pending CN110201003A (zh) 2012-02-29 2013-02-28 微生物区系的组合物及与其相关的方法
CN201380022545.6A Pending CN104780932A (zh) 2012-02-29 2013-02-28 微生物区系的组合物及与其相关的方法
CN201810321009.0A Pending CN108771687A (zh) 2012-02-29 2013-02-28 微生物区系的组合物及与其相关的方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN201380022545.6A Pending CN104780932A (zh) 2012-02-29 2013-02-28 微生物区系的组合物及与其相关的方法
CN201810321009.0A Pending CN108771687A (zh) 2012-02-29 2013-02-28 微生物区系的组合物及与其相关的方法

Country Status (6)

Country Link
US (11) US9173910B2 (enExample)
EP (1) EP2836224A4 (enExample)
CN (3) CN110201003A (enExample)
BR (1) BR112014021388A2 (enExample)
IN (1) IN2014DN07752A (enExample)
WO (1) WO2013130773A2 (enExample)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK4032586T3 (da) 2010-02-01 2025-11-10 Ferring Microbiome Inc Bakterieterapi til clostridium difficile-colitis
WO2013130773A2 (en) 2012-02-29 2013-09-06 Ethicon Endo-Surgery, Inc. Compositions of microbiota and methods related thereto
WO2014075745A1 (en) * 2012-11-19 2014-05-22 Université Catholique de Louvain Use of akkermansia for treating metabolic disorders
CN105378739B (zh) * 2012-12-13 2019-09-27 麦太宝根有限公司 鉴定有发生2型糖尿病风险的人
GB2535034A (en) 2013-07-21 2016-08-10 Whole Biome Inc Methods and systems for microbiome characterization, monitoring and treatment
US9557331B2 (en) 2013-08-23 2017-01-31 Elwha Llc Systems, methods, and devices for assessing microbiota of skin
US9805171B2 (en) 2013-08-23 2017-10-31 Elwha Llc Modifying a cosmetic product based on a microbe profile
US9549703B2 (en) 2013-11-27 2017-01-24 Elwha Llc Devices and methods for sampling and profiling microbiota of skin
US9526480B2 (en) 2013-11-27 2016-12-27 Elwha Llc Devices and methods for profiling microbiota of skin
US20150057623A1 (en) * 2013-08-23 2015-02-26 Elwha Llc Systems, Methods, and Devices for Delivering Treatment to a Skin Surface
US10010704B2 (en) 2013-08-23 2018-07-03 Elwha Llc Systems, methods, and devices for delivering treatment to a skin surface
US9811641B2 (en) 2013-08-23 2017-11-07 Elwha Llc Modifying a cosmetic product based on a microbe profile
US10152529B2 (en) 2013-08-23 2018-12-11 Elwha Llc Systems and methods for generating a treatment map
US9610037B2 (en) 2013-11-27 2017-04-04 Elwha Llc Systems and devices for profiling microbiota of skin
US9526450B2 (en) 2013-11-27 2016-12-27 Elwha Llc Devices and methods for profiling microbiota of skin
WO2015164555A1 (en) * 2014-04-23 2015-10-29 Cornell University Modulation of fat storage in a subject by altering population levels of christensenellaceae in the gi tract
PL3138031T3 (pl) 2014-04-28 2023-04-11 Yeda Research And Development Co., Ltd. Sposób i urządzenie do przewidywania odpowiedzi na pokarm
KR101740893B1 (ko) 2014-05-20 2017-06-13 주식회사 엠디헬스케어 Ａｋｋｅｒｍａｎｓｉａ ｍｕｃｉｎｉｐｈｉｌａ 균에서 유래하는 세포밖 소포를 유효성분으로 함유하는 대사질환의 치료 또는 예방용 조성물
WO2015178653A1 (ko) * 2014-05-20 2015-11-26 이화여자대학교 산학협력단 Akkermansia muciniphila 균에서 유래하는 세포밖 소포를 유효성분으로 함유하는 대사질환의 치료 또는 예방용 조성물
WO2016033439A2 (en) * 2014-08-28 2016-03-03 Yale University Compositions and methods for the treating an inflammatory disease or disorder
EP3769777B9 (en) * 2014-10-02 2022-10-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Pharmaceutical and food compositions for inducing satiation and prolonging satiety in subjects in need thereof
EP4529950A3 (en) 2014-10-31 2025-08-20 Pendulum Therapeutics, Inc. Methods and compositions relating to microbial treatment
JP6893885B2 (ja) * 2015-01-26 2021-06-23 インターナショナル ディハイドレーティッド フーズ， インコーポレイテッド ブロス組成物およびプレバイオティクスとしてのその使用
PL3292135T3 (pl) 2015-05-06 2023-01-02 Wageningen Universiteit Zastosowanie polipeptydu do wpływania na sygnalizację odpornościową i/lub wpływania na funkcję bariery jelitowej i/lub modulowania stanu metabolicznego
EP3915552A1 (en) 2015-06-01 2021-12-01 Xeno Biosciences Inc. Compositions for use in modulating the gut microbiota and managing weight
EP3307906B1 (en) * 2015-06-09 2020-10-14 Regents of the University of Minnesota Methods for detecting risk of having a bloodstream infection
US10828340B2 (en) 2015-06-09 2020-11-10 Rebiotix, Inc. Microbiota restoration therapy (MRT) compositions and methods of manufacture
CN114276960A (zh) * 2015-09-10 2022-04-05 卢万天主教大学 经巴氏灭菌的艾克曼菌用于治疗代谢病症的用途
US11066711B2 (en) 2015-12-08 2021-07-20 Mayo Foundation For Medical Education And Research Biomarkers for predicting Clostridium difficile infection treatment outcome
CN109069558A (zh) 2016-03-04 2018-12-21 加利福尼亚大学董事会 微生物聚生体及其用途
EP3442546A4 (en) 2016-04-15 2020-03-25 National Health Research Institutes ANTI-OBESITY MICROBIOTE COMPOSITIONS AND METHODS OF PREPARATION AND USES THEREOF
US10293005B2 (en) 2016-04-19 2019-05-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of gram negative species to treat atopic dermatitis
WO2017184601A1 (en) 2016-04-19 2017-10-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of gram negative species to treat atopic dermatitis
US9999641B2 (en) 2016-06-14 2018-06-19 Vedanta Biosciences, Inc. Treatment of clostridium difficile infection
CA3226196A1 (en) 2016-06-14 2017-12-21 Vedanta Biosciences, Inc. Treatment of clostridium difficile infection
US20180030403A1 (en) 2016-07-28 2018-02-01 Bobban Subhadra Devices, systems and methods for the production of humanized gut commensal microbiota
US10441612B2 (en) * 2016-08-16 2019-10-15 Taichung Veterans General Hospital Intestinal microbe therapy, composition therefor and method for preparing the same
WO2018102469A1 (en) 2016-11-30 2018-06-07 Xeno Biosciences Inc. Pharmaceutical preparations and methods to manage weight and to modulate the gut microbiota
CN107043714B (zh) * 2016-12-13 2021-03-12 广州康泽医疗科技有限公司 一种益生菌及其制备方法
WO2018136884A1 (en) * 2017-01-23 2018-07-26 The Regents Of The University Of California Compositions and methods for treating obesity and inducing weight loss
AU2018326705A1 (en) 2017-08-30 2020-03-05 Pendulum Therapeutics, Inc. Methods and compositions for treatment of microbiome-associated disorders
EP3695017A1 (en) * 2017-10-13 2020-08-19 Rebiotix, Inc. Microbiome health index
WO2019118984A2 (en) 2017-12-15 2019-06-20 Solarea Bio, Inc. Microbial compositions and methods for treating type 2 diabetes, obesity, and metabolic syndrome
US20200345036A1 (en) * 2018-01-04 2020-11-05 White Dog Labs, Inc. Method and composition for improving health of an animal comprising cells of organism consisting of the strains within the order clostridiales
CN113038957A (zh) 2018-04-10 2021-06-25 谢尔塔治疗公司 微生物群
MX2020012018A (es) 2018-05-11 2021-03-02 Forte Subsidiary Inc Composiciones para el tratamiento de condiciones de la piel.
EP3823651A4 (en) 2018-07-19 2022-04-27 Pendulum Therapeutics, Inc. METHODS AND COMPOSITIONS FOR MICROBIAL TRANSPLANTATION
EP3836946A4 (en) 2018-08-17 2022-05-04 Vedanta Biosciences, Inc. METHOD OF REDUCING DYSBIosis AND RECOVERING A MICROBIOME
US11980647B2 (en) 2018-09-05 2024-05-14 Solarea Bio, Inc. Methods and compositions for treating musculoskeletal diseases, treating inflammation, and managing symptoms of menopause
WO2020051379A1 (en) 2018-09-05 2020-03-12 Solarea Bio, Inc. Methods and compositions for treating musculoskeletal diseases
CA3110738A1 (en) 2018-09-18 2020-03-26 Mcpharma Biotech Inc. Detection, treatment, and monitoring of microbiome-induced metabolic dysfunction
CN110964650B (zh) * 2018-09-27 2022-10-11 上海上药信谊药厂有限公司 一种用于预防和治疗代谢疾病的菌株及其应用
ES2763874B2 (es) * 2018-11-30 2020-10-13 Consejo Superior Investigacion Phascolarctobacterium faecium para su uso en la prevencion y tratamiento de la obesidad y sus comorbilidades
EP4010315A4 (en) * 2019-08-09 2023-11-15 The Regents of the University of California COMPOSITIONS AND METHODS FOR TREATING METABOLIC DISEASES
CN115087727B (zh) * 2019-09-25 2025-03-18 健康生物公司 用于癌症治疗的专性厌氧人肠道微生物及其用途
KR20220108765A (ko) 2019-10-07 2022-08-03 시올타 테라퓨틱스, 인크. 치료용 약학 조성물
DK180598B1 (da) * 2020-02-21 2021-10-14 Sander Wilbek Theis Stivelsespropanoat anvendt som tilsætningsstof og/eller kosttilskud til mennesker til forebyggelse af overvægt og fedme
CN111388488A (zh) * 2020-04-10 2020-07-10 中国海洋大学 半乳寡糖及其衍生物在作为防治非酒精性脂肪肝药物中的应用
EP4181910A4 (en) * 2020-07-17 2024-06-05 DSM Nutritional Products, LLC OLIGOSACCHARIDE COMPOSITIONS AND METHODS OF USE
BE1028339B1 (fr) 2020-11-09 2021-12-21 A Mansia Biotech Composition comprenant de l'Akkermansia muciniphila et de l'extrait de thé vert
WO2022155443A1 (en) * 2021-01-15 2022-07-21 Yale University Compositions and methods for treating and preventing diseases or disorders using inter-species interactions
US20240268432A1 (en) 2021-07-23 2024-08-15 Universidade Católica Portuguesa - Ucp Encapsulated bacterial, methods and uses thereof
CA3238788A1 (en) 2021-11-22 2023-05-25 Eric Michael Schott Methods and compositions for treating musculoskeletal diseases, treating inflammation, and managing symptoms of menopause
US20230190834A1 (en) 2021-12-21 2023-06-22 Solarea Bio, Inc. Immunomodulatory compositions comprising microbial entities

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1850047A (zh) * 2006-06-01 2006-10-25 济南帅华医药科技有限公司 一种含β－内酰胺酶抑制剂和头孢菌素的缓释制剂及其应用
WO2009024429A2 (en) * 2007-08-17 2009-02-26 Nestec S.A. Gut flora and weight management
US20100172874A1 (en) * 2006-12-18 2010-07-08 The Washington University Gut microbiome as a biomarker and therapeutic target for treating obesity or an obesity related disorder
CN105030841A (zh) * 2015-08-24 2015-11-11 上海交通大学医学院附属瑞金医院 Akkermansia muciniphila BAA-835菌株的应用

Family Cites Families (133)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1423823A (fr) 1964-11-20 1966-01-07 Azote Office Nat Ind Procédé de reformage catalytique et sous pression élevée des hydrocarbures pétroliers par la vapeur
US3625214A (en) 1970-05-18 1971-12-07 Alza Corp Drug-delivery device
US4906474A (en) 1983-03-22 1990-03-06 Massachusetts Institute Of Technology Bioerodible polyanhydrides for controlled drug delivery
US4789734A (en) 1985-08-06 1988-12-06 La Jolla Cancer Research Foundation Vitronectin specific cell receptor derived from mammalian mesenchymal tissue
NL8720442A (nl) 1986-08-18 1989-04-03 Clinical Technologies Ass Afgeefsystemen voor farmacologische agentia.
US5143845A (en) 1986-09-03 1992-09-01 Toa Pharmaceutical Co., Ltd. Mixture of saccarifying lactic acid producing and butyric acid producing bacteria
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US6024983A (en) 1986-10-24 2000-02-15 Southern Research Institute Composition for delivering bioactive agents for immune response and its preparation
US4897268A (en) 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
US5443826A (en) 1988-08-02 1995-08-22 Borody; Thomas J. Treatment of gastro-intestinal disorders with a fecal composition or a composition of bacteroides and E. Coli
EP0433299B1 (en) 1988-08-02 1998-05-06 Gastro Services Pty. Limited (ACN 002 994 890) Treatment of gastro-intestinal disorders
JP2961182B2 (ja) 1990-03-09 1999-10-12 ミヤリサン株式会社 クロストリジウム・ディフィシル下痢症および偽膜性大腸炎の予防ならびに治療用医薬組成物
JP2961184B2 (ja) 1990-05-07 1999-10-12 ミヤリサン株式会社 クロストリジウム・ディフィシル下痢症および偽膜性大腸炎の予防ならびに治療用医薬組成物
DK0678034T3 (da) 1993-01-11 1999-11-08 Dana Farber Cancer Inst Inc Induktion af cytotoksiske T-lymfocytreaktioner
GB9306473D0 (en) 1993-03-29 1993-05-19 Bioglan Lab Ltd Pharmaceutically useful compounds
US5531989A (en) 1994-10-28 1996-07-02 Metagenics, Inc. Immunoglobulin and fiber-containing composition for human gastrointestinal health
US6241983B1 (en) 1994-10-28 2001-06-05 Metagenics, Inc. Bacteria-and fiber-containing composition for human gastrointestinal health
JP2002511777A (ja) 1996-10-28 2002-04-16 ゼネラル ミルズ，インコーポレイテッド 調放性粒子の埋包およびカプセル化
SK3482001A3 (en) 1998-09-17 2002-02-05 Baxter Healthcare Sa Streptococcal c beta protein compositions
NZ512275A (en) 1998-12-11 2003-11-28 Urex Biotech Inc Probiotic therapy delivered to women by oral administration of selected lactobascilli that have antagonistic properties against urogenital pathogens
ID29150A (id) 1999-01-15 2001-08-02 Entpr Ireland Cs Penggunaan lactobacillus salivarius
US7056661B2 (en) 1999-05-19 2006-06-06 Cornell Research Foundation, Inc. Method for sequencing nucleic acid molecules
CN1186440C (zh) 1999-08-05 2005-01-26 雀巢制品公司 预防病原性细菌引起的腹泻的新双歧杆菌
JP4580542B2 (ja) 2000-05-17 2010-11-17 株式會社バイオニア 肥満又は糖尿病治療用微生物及びその微生物を含む医薬組成物
US20040170617A1 (en) 2000-06-05 2004-09-02 Finegold Sydney M. Method of treating diseases associated with abnormal gastrointestinal flora
US20020013270A1 (en) 2000-06-05 2002-01-31 Bolte Ellen R. Method for treating a mental disorder
US20040062757A1 (en) 2001-06-05 2004-04-01 Finegold Sydney M. Method of testing gastrointestinal diseases associated with species of genus clostridium
FI110668B (fi) 2000-06-20 2003-03-14 Aboatech Ab Oy Probioottien käyttö atooppisten sairauksien primaariseen ehkäisyyn
AUPQ899700A0 (en) 2000-07-25 2000-08-17 Borody, Thomas Julius Probiotic recolonisation therapy
EP1227152A1 (en) 2001-01-30 2002-07-31 Société des Produits Nestlé S.A. Bacterial strain and genome of bifidobacterium
WO2002062360A1 (en) 2001-02-06 2002-08-15 Societe Des Produits Nestle S.A. Endotoxin binding by lactic acid bacteria and bifidobacteria
WO2002085415A1 (en) 2001-04-17 2002-10-31 Biomatrix, Inc Non-digestible sugar-coated products and process
US7101565B2 (en) 2002-02-05 2006-09-05 Corpak Medsystems, Inc. Probiotic/prebiotic composition and delivery method
DK1478329T3 (da) 2002-02-21 2006-08-28 Nestle Sa Præparat til oral indgivelse tikl beskyttelse af huden mod lys
ITBO20020564A1 (it) 2002-09-06 2004-03-07 Alfa Wassermann Spa Bifidobatteri e preparazioni che li contengono.
SE526711C2 (sv) 2003-01-31 2005-10-25 Probi Ab Nya stammar av Bifidobacterium med förmåga att överleva i magtarmkanalen och producera glutamin in vivo, samt kompositioner och användningar därav
CA2559596A1 (en) 2003-03-13 2004-11-25 Universite De Moncton (Bureau De Soutien A L'innovation) Antioxidant producing bacterium and uses thereof
GB0307026D0 (en) 2003-03-27 2003-04-30 Rowett Res Inst Bacterial supplement
EP1462116A1 (en) 2003-03-29 2004-09-29 Villitech SARL Composition for treating the gastrointestinal tract
US8192733B2 (en) 2003-08-29 2012-06-05 Cobb & Associates Probiotic composition useful for dietary augmentation and/or combating disease states and adverse physiological conditions
US20050100559A1 (en) 2003-11-07 2005-05-12 The Procter & Gamble Company Stabilized compositions comprising a probiotic
EP1600060A1 (en) 2004-05-25 2005-11-30 Cognis IP Management GmbH Oral and/or topical compositions comprising prebiotics and fatty acid
MXPA06015184A (es) 2004-06-23 2007-11-22 Nestec Sa Procedimiento y composiciones utiles para prevenir y/o tratar pieles sensibles y/o secas.
US7862808B2 (en) 2004-07-01 2011-01-04 Mead Johnson Nutrition Company Method for preventing or treating respiratory infections and acute otitis media in infants using Lactobacillus rhamnosus LGG and Bifidobacterium lactis Bb-12
ITMI20041550A1 (it) 2004-07-29 2004-10-29 Proge Farm Srl Uso di batteri probiotici per la preparazione di composizioni topiche per la protezione dell'epidermide
FR2874825B1 (fr) 2004-09-08 2006-12-08 Genibio Sarl Utilisations d'oligosaccharides prebiotiques benefiques pour la flore vaginale
US20060115485A1 (en) 2004-10-29 2006-06-01 Medimmune, Inc. Methods of preventing and treating RSV infections and related conditions
US20060115465A1 (en) 2004-10-29 2006-06-01 Macfarlane George Treatment of gastrointestinal disorders
JP4953824B2 (ja) 2004-12-28 2012-06-13 Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 宿主に対して抗病性を付与する新規な菌株および菌体組成物
TW200700074A (en) 2005-03-04 2007-01-01 Calpis Co Ltd Inducer of t cell apoptosis
US20070042953A1 (en) 2005-08-16 2007-02-22 Bazan Nicolas G Antiepileptogenic complex of albumin with docosahexaenoate
FR2889958A1 (fr) 2005-08-25 2007-03-02 Lyoct Sa Lab Utilisation d'un symbiotique pour le traitement de la dermatite atopique
EP1776877A1 (en) 2005-10-21 2007-04-25 N.V. Nutricia Method for stimulating the intestinal flora
ITRM20060237A1 (it) 2006-05-03 2007-11-04 Anabasis S R L Uso dei probiotici nella prevenzione e nel trattamento delle congiuntiviti allergiche
WO2007136719A2 (en) * 2006-05-18 2007-11-29 Biobalance Llc Biotherapeutic compositions comprising probiotic escherichia coli and uses thereof
JP5019563B2 (ja) 2006-06-16 2012-09-05 旭化成ケミカルズ株式会社 腸内細菌賦活剤
CN101095698B (zh) 2006-06-26 2010-12-01 青岛东海药业有限公司 酪酸梭菌防治便臭毒素引起的相关症状和疾病的用途
US20080069861A1 (en) 2006-09-19 2008-03-20 National Starch And Chemical Investment Holding Corporation Probiotic/Non-Probiotic Combinations
US9644210B2 (en) 2007-02-22 2017-05-09 Jürgen Schrezenmeir Probiotic gram-positive bacteria for the prophylaxis, suppression, or elimination of allergic reactions in human
MX2009010419A (es) 2007-03-28 2010-02-18 Alimentary Health Ltd Cepas de bacterias bifidas probioticas.
CA2682327A1 (en) 2007-03-28 2008-10-02 Alimentary Health Limited Probiotic bifidobacterium strains
ES2683334T3 (es) 2007-05-03 2018-09-26 Tobias Olofsson Nuevas bacterias aisladas del tracto productor de miel de abejas melíferas
TW200904340A (en) 2007-05-11 2009-02-01 Mannatech Inc Processing of natural polysaccharides by selected non-pathogenic microorganisms and methods of making and using the same
DK1992351T3 (en) 2007-05-18 2016-06-06 Nestec Sa Lactobacillus johnsonii for the prevention of post-surgical infection
US20090010892A1 (en) 2007-07-06 2009-01-08 Toa Pharmaceutical Co., Ltd. Hyperlipidemia Treatment Agent
US20090010891A1 (en) 2007-07-06 2009-01-08 Toa Pharmaceutical Co., Ltd. Sepsis Treatment Agent
EP2184997A4 (en) 2007-07-31 2010-11-03 Univ New York DIAGNOSIS AND TREATMENT METHODS FOR THE CHARACTERIZATION OF BACTERIAL MICROORGANISMS IN SKIN DISEASES
WO2009043856A2 (en) 2007-10-01 2009-04-09 University College Cork, National University Of Ireland, Cork Modulation of tissue fatty acid composition of a host by human gut bacteria
US8478544B2 (en) 2007-11-21 2013-07-02 Cosmosid Inc. Direct identification and measurement of relative populations of microorganisms with direct DNA sequencing and probabilistic methods
US20090143759A1 (en) 2007-11-30 2009-06-04 Jacques Van Dam Methods, Devices, Kits and Systems for Defunctionalizing the Cystic Duct
EP2072052A1 (en) 2007-12-17 2009-06-24 Nestec S.A. Prevention of opportunistic infections in immune-compromised subjects
ES2343499B1 (es) 2007-12-24 2011-06-10 Consejo Superior De Investigaciones Cientificas Microorganismos para mejorar el estado de salud de individuos con desordenes relacionados con la ingesta de gluten.
EP2110028A1 (en) 2008-04-15 2009-10-21 Nestec S.A. Bifidobacterium longum and hippocampal BDNF expression
US20110177034A1 (en) 2008-07-11 2011-07-21 Chr-Hansen A/S Probiotic bifidobacterium longum
WO2010030781A2 (en) 2008-09-10 2010-03-18 Numed International, Inc. Aromatic carboxylic acid derivatives for treatment and prophylaxis of gastrointestinal diseases including colon cancer
US9603876B2 (en) 2008-09-25 2017-03-28 New York University Compositions and methods for restoring gastrointestinal microbiota following antibiotic treatment
WO2010040055A2 (en) * 2008-10-03 2010-04-08 Intekrin Therapeutics, Inc. Oral pharmaceutical formulations for antidiabetic compounds
BRPI0921758A2 (pt) 2008-11-11 2019-07-30 Alimentary Health Ltd bifidobacterium longum
US8785160B2 (en) 2009-02-24 2014-07-22 Ritter Pharmaceuticals, Inc. Prebiotic formulations and methods of use
MX2011011659A (es) 2009-05-07 2012-02-28 Tate & Lyle Ingredients France SAS Composiciones y metodos para elaborar alfa-(1,6) oligodextranos ramificados en alfa-(1,2).
ES2559008T3 (es) 2009-05-11 2016-02-10 Nestec S.A. Bifidobacterium longum NCC2705 no replicante y trastornos inmunitarios
EP2808024B1 (en) 2009-06-19 2019-04-24 DuPont Nutrition Biosciences ApS Bifidobacteria for treating congestive heart failure
US20150320808A1 (en) 2009-06-19 2015-11-12 Dupont Nutrition Biosciences Aps Bifidobacteria for treating cardiac conditions
US9848760B2 (en) 2009-06-29 2017-12-26 Gearbox, Llc Devices for continual monitoring and introduction of gastrointestinal microbes
EP2459203B1 (en) 2009-07-30 2018-10-31 DuPont Nutrition Biosciences ApS Lactic acid bacteria and bifidobacteria for treating endotoxemia
DK2289527T3 (en) 2009-08-25 2018-04-23 Nestec Sa BIFIDOBACTERIUM LONGUM AND FUNCTIONAL GI DISEASES
WO2011043654A1 (en) 2009-10-05 2011-04-14 Aak Patent B.V. Methods for diagnosing irritable bowel syndrome
US20110081320A1 (en) 2009-10-06 2011-04-07 Nubiome, Inc. Treatment/Cure of Autoimmune Disease
BR112012011294B1 (pt) 2009-11-12 2018-03-20 Nestec S.A. Composição nutricional para administração a um indivíduo
DK2513292T3 (da) 2009-12-16 2017-11-13 Probiotical Spa Konjugeret linolsyre-producerende stammer af probiotiske bakterier og anvendelse deraf til fremstillingen af en farmaceutisk sammensætning
US9504750B2 (en) 2010-01-28 2016-11-29 Advanced Bionutrition Corporation Stabilizing composition for biological materials
NL2004201C2 (en) 2010-02-05 2011-08-08 Friesland Brands Bv Use of sialyl oligosaccharides to modulate the immune system.
BR112012020003A2 (pt) 2010-02-10 2020-08-18 Japan Eco-Science Co., Ltd. mistura, solução de dissolução e agente farmacêutico cada um compreendendo micro-organismo termofílico
IT1398553B1 (it) 2010-03-08 2013-03-01 Probiotical Spa Composizione comprendente batteri probiotici per il trattamento di patologie associate con le alterazioni del sistema immunitario.
FI20105478A0 (fi) 2010-04-30 2010-04-30 Valtion Teknillinen Menetelmä tyypin 1 diabeteksen diagnosoimiseksi ja menetelmiä ja koostumuksia tyypin 1 diabeteksen puhkeamisen estämiseksi
US8951512B2 (en) * 2010-05-04 2015-02-10 New York University Methods for treating bone disorders by characterizing and restoring mammalian bacterial microbiota
WO2011151941A1 (ja) 2010-06-04 2011-12-08 国立大学法人東京大学 制御性ｔ細胞の増殖または集積を誘導する作用を有する組成物
KR101757504B1 (ko) 2010-06-28 2017-07-12 가부시키가이샤 야쿠르트 혼샤 경구용 피부 성상 개선제
KR101850166B1 (ko) 2010-06-30 2018-04-18 네스텍 소시에테아노님 피부 색소침착 조절용 식품 보충제에서의 치커리산 및 락틱 박테리아의 용도
US9386793B2 (en) 2010-08-20 2016-07-12 New York University Compositions and methods for treating obesity and related disorders by characterizing and restoring mammalian bacterial microbiota
CA2811056A1 (en) 2010-09-10 2012-03-15 Viropharma Incorporated Environmental clostridial bacteriotherapy and related formulations and methods of manufacture and use
PL2944690T3 (pl) 2010-10-11 2018-05-30 Jennewein Biotechnologie Gmbh Nowe fukozylotransferazy i ich zastosowanie
US20120165792A1 (en) 2010-12-22 2012-06-28 Ethicon Endo-Surgery, Inc. Pill Catchers
US10245288B2 (en) 2011-02-04 2019-04-02 Joseph E. Kovarik Method and system for reducing the likelihood of developing NASH in an individual diagnosed with non-alcoholic fatty liver disease
CN103687604A (zh) 2011-03-01 2014-03-26 群体创新有限责任公司 用于治疗与致病生物膜相关之病症的材料和方法
AU2012225305B2 (en) * 2011-03-09 2017-06-08 Regents Of The University Of Minnesota Compositions and methods for transplantation of colon microbiota
WO2012142605A1 (en) 2011-04-15 2012-10-18 Samaritan Health Services Rapid recolonization deployment agent
ITMI20110793A1 (it) 2011-05-09 2012-11-10 Probiotical Spa Ceppi di batteri probiotici e composizione sinbiotica contenente gli stessi destinata alla alimentazione dei neonati.
EP2797606A4 (en) 2011-08-17 2015-09-30 MicroBiome Therapeutics LLC COMPOSITION AND USE OF A FORMULATION TO INCREASE THE RELATIONSHIP OF GASTROINTESTINAL MICROBOTS IN PLANT STEM BACTERIITIES FOR MICROBOTS OF THE FIRMUCES PLANT STAMM
DK2744888T3 (en) 2011-08-18 2018-03-12 Chr Hansen As Process for purifying bacterial cells
DK2753187T4 (da) 2011-08-30 2025-10-20 Caelus Pharmaceuticals B V Fremgangsmåde til forebyggelse og/eller behandling af insulinresistens
ES2662793T3 (es) 2011-09-14 2018-04-09 Nubiyota Llc Complementos de medio y métodos para cultivar microorganismos anaerobios gastrointestinales humanos
US20130121968A1 (en) 2011-10-03 2013-05-16 Atossa Genetics, Inc. Methods of combining metagenome and the metatranscriptome in multiplex profiles
FI20116008A0 (fi) 2011-10-12 2011-10-12 Maeyrae Maekinen Annika Viskeraalisen rasvan estäminen ja diagnostisointi
WO2013067185A1 (en) 2011-11-02 2013-05-10 Bios Llc Probiotic stick formulation for skin maintenance and methods of use
JP6306507B2 (ja) 2011-12-01 2018-04-18 国立大学法人 東京大学 制御性ｔ細胞の増殖または集積を誘導するヒト由来細菌
MY172363A (en) 2011-12-07 2019-11-21 Asahi Group Holdings Ltd Lipid metabolism and/or sugar metabolism improver containing lactic acid bacterium or treatment product thereof
WO2013130773A2 (en) 2012-02-29 2013-09-06 Ethicon Endo-Surgery, Inc. Compositions of microbiota and methods related thereto
ES2436251B1 (es) 2012-05-25 2014-10-08 Consejo Superior De Investigaciones Científicas (Csic) Bacteroides cect 7771 y su uso en la prevención y tratamiento de sobrepeso, obesidad y alteraciones metabólicas e inmunológicas.
US20130344042A1 (en) 2012-06-20 2013-12-26 Gretchen Tanbonliong Dietary management of celiac disease and food allergy
WO2014011233A1 (en) 2012-07-09 2014-01-16 Trachtman Ira Milton Compositions and method for treatment and prophylaxis of inflammatory bowel disease
US10954486B2 (en) 2012-08-20 2021-03-23 Chr. Hansen A/S Method for freeze drying a bacteria-containing concentrate
CA3092314A1 (en) 2012-09-20 2014-03-27 Prothera, Inc. Probiotic compositions and methods for the treatment of obesity and obesity-related conditions
AU2013338774B2 (en) 2012-11-01 2017-03-02 Academisch Ziekenhuis Groningen Methods and compositions for stimulating beneficial bacteria in the gastrointestinal tract
EP4509182A3 (en) 2012-11-19 2025-05-21 Université Catholique de Louvain Utilisation d'akkermansia pour le traitement de troubles métaboliques
WO2014075745A1 (en) 2012-11-19 2014-05-22 Université Catholique de Louvain Use of akkermansia for treating metabolic disorders
EP4233545A3 (en) 2012-11-23 2023-10-18 Seres Therapeutics, Inc. Synergistic bacterial compositions and methods of production and use thereof
US8906668B2 (en) 2012-11-23 2014-12-09 Seres Health, Inc. Synergistic bacterial compositions and methods of production and use thereof
HK1218559A1 (zh) 2013-02-04 2017-02-24 Seres Therapeutics, Inc. 抑制致病细菌生长的配方和方法
HK1218560A1 (zh) 2013-02-04 2017-02-24 Seres Therapeutics, Inc. 组成与方法
WO2014153194A2 (en) 2013-03-14 2014-09-25 Seres Health, Inc. Methods for pathogen detection and enrichment from materials and compositions
US11814664B2 (en) 2013-05-24 2023-11-14 Genomatica, Inc. Microorganisms and methods for producing (3R)-hydroxybutyl (3R)-hydroxybutyrate
CN105106245A (zh) 2015-08-24 2015-12-02 上海交通大学医学院附属瑞金医院 Akkermansia muciniphila BAA-835菌株的应用

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1850047A (zh) * 2006-06-01 2006-10-25 济南帅华医药科技有限公司 一种含β－内酰胺酶抑制剂和头孢菌素的缓释制剂及其应用
US20100172874A1 (en) * 2006-12-18 2010-07-08 The Washington University Gut microbiome as a biomarker and therapeutic target for treating obesity or an obesity related disorder
WO2009024429A2 (en) * 2007-08-17 2009-02-26 Nestec S.A. Gut flora and weight management
CN105030841A (zh) * 2015-08-24 2015-11-11 上海交通大学医学院附属瑞金医院 Akkermansia muciniphila BAA-835菌株的应用

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
TULIKA ARORA等: "Propionate. Anti-obesity and satiety enhancing factor?", 《APPETITE》 *
ZHANG HUSEN等: "Human gut microbiota in obesity and after gastric bypass", 《PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA》 *
姬秋和等: "2型糖尿病发病机制中的肠道因素", 《临床内科杂志》 *
曾艳华等: "大蒜多糖对人体肠道中拟杆菌生长的影响", 《现代食品科技》 *

Also Published As

Publication number Publication date
US20200237835A1 (en) 2020-07-30
CN104780932A (zh) 2015-07-15
BR112014021388A2 (pt) 2017-07-18
US10149870B2 (en) 2018-12-11
US20200121733A1 (en) 2020-04-23
EP2836224A2 (en) 2015-02-18
US10149867B2 (en) 2018-12-11
US20200121734A1 (en) 2020-04-23
US20130224155A1 (en) 2013-08-29
WO2013130773A3 (en) 2014-12-18
CN108771687A (zh) 2018-11-09
US20200121732A1 (en) 2020-04-23
US20160113971A1 (en) 2016-04-28
US10729732B2 (en) 2020-08-04
IN2014DN07752A (enExample) 2015-05-15
US9173910B2 (en) 2015-11-03
US20170368108A1 (en) 2017-12-28
US20200246395A1 (en) 2020-08-06
EP2836224A4 (en) 2015-12-16
WO2013130773A2 (en) 2013-09-06
US11590176B2 (en) 2023-02-28
US20200121736A1 (en) 2020-04-23
US20190046590A1 (en) 2019-02-14
WO2013130773A8 (en) 2014-10-16
US12048721B2 (en) 2024-07-30
US20200121735A1 (en) 2020-04-23

Similar Documents

Publication Publication Date Title
US12048721B2 (en) Compositions of microbiota and methods related thereto
Wang et al. Gut microbiota mediates the anti-obesity effect of calorie restriction in mice
Heeney et al. Lactobacillus plantarum bacteriocin is associated with intestinal and systemic improvements in diet-induced obese mice and maintains epithelial barrier integrity in vitro
Louis et al. The gut microbiota, bacterial metabolites and colorectal cancer
Villanueva-Millán et al. Gut microbiota: a key player in health and disease. A review focused on obesity
US12257272B2 (en) Method and system for reducing the likelihood of developing depression in an individual
Ojeda et al. Nutritional modulation of gut microbiota—The impact on metabolic disease pathophysiology
CN111212655A (zh) 用于治疗胆汁淤积性疾病的组合物和方法
JP2018532779A (ja) 糖尿病及び腸疾患の治療又は予防における使用のためのフィーカリバクテリウムプラウスニッツィ及びデスルホビブリオピゲル
Koulas et al. Gut microbiota in patients with morbid obesity before and after bariatric surgery: a ten-year review study (2009–2019)
US11969445B2 (en) Probiotic composition and method for controlling excess weight, obesity, NAFLD and NASH
JP6475162B2 (ja) プレバイオティックチラコイド組成物
Huang et al. Orlistat ameliorates lipid dysmetabolism in high-fat diet-induced mice via gut microbiota modulation
Wu et al. GOS‐Modulated Gut Microbiota in Mice Ameliorates Obesity in High‐Fat Diet‐Fed Mice Through the Gut‐Liver Axis and Bile Acid Pathway
Basso et al. Microbiota Organ and Bariatric Surgery
Wang et al. 922 Angiotensin Converting Enzyme Modulates Epithelial Cell Apoptosis in a Massive Intestinal Resection Rat Model: Role of At1r Receptor
CN115245523A (zh) 青春双歧杆菌在制备脂肪吸收抑制剂中的应用
Barnes et al. 923 The Addition of Synbiotics to Partial Enteral Nutrition Enhances Intestinal Adaptation in a Piglet Model of Intestinal Failure
Ramadass et al. 924 Glutamine Attenuates the Toxic Effects of Legumes via Stimulation of HSP Production
Rodier by Hugo Rodier, MD

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right

Effective date of registration: 20230410

Address after: new jersey

Applicant after: JOHNSON & JOHNSON CONSUMER COMPANIES, Inc.

Applicant after: THE GENERAL Hospital Corp.

Applicant after: PRESIDENT AND FELLOWS OF HARVARD College

Address before: Ohio State

Applicant before: ETHICON ENDO-SURGERY, Inc.

Applicant before: THE GENERAL Hospital Corp.

Applicant before: PRESIDENT AND FELLOWS OF HARVARD College

TA01 Transfer of patent application right